Syschem (India) Limited is an India-based company, which is engaged in the business of manufacturing of active pharmaceutical ingredient (API) / Intermediates. The Company operates through pharmaceuticals segment. The Company’s API/ Intermediates products include Amoxycillin Trihydrate; Ampicillin Trihydrate; Cloxacillin Sodium; Dicloxacillin Sodium; Flucloxacillin Sodium for export only; Cephalexin; Cefixime; Cefadroxil; Distillation of Specialty Solvents, such as dimethylformamide (DMF), acetonitrile, ethyl acetate and tetrahydrofuran (THF). It also engaged in the manufacturing of bulk drugs/ intermediates / specialty chemicals and contract manufacturing. The Company has its manufacturing facility at Village Bargodam, Tehsil Kalka, Distt. Panchkula Haryana.
SYSCHEM (INDIA) LTD. Financial Highlights
- Revenue: SYSCHEM (INDIA) LTD. reported revenue of ₹573.79 crore in FY26 vs ₹331.72 crore in FY25. It showed an increase of 72.97% on a yearly basis.
- Operating Profit: SYSCHEM (INDIA) LTD. reported an operating profit of ₹14.79 crore in FY26 vs ₹1.01 crore in FY25. It showed an increase of 1,364.36% on a year-on-year basis.
- Net Profit: SYSCHEM (INDIA) LTD. reported a net profit of ₹10.93 crore in FY26 vs ₹0.46 crore in FY25. It showed an increase of 2,276.09% on a yearly basis.
SYSCHEM (INDIA) LTD. Quarterly Result Highlights
- SYSCHEM (INDIA) LTD. reported revenue of ₹109.26 crore in Jun 2026, compared with ₹219.35 crore in Mar 2026, representing a decrease of 50.19% on a quarter-on-quarter (QoQ) basis.
- SYSCHEM (INDIA) LTD. reported an operating loss of ₹1.45 crore in Jun 2026, compared with ₹5.60 crore in Mar 2026, representing a decrease of 125.89% on a quarter-on-quarter (QoQ) basis.
- SYSCHEM (INDIA) LTD. reported a loss of ₹1.67 crore in Jun 2026, compared with ₹1.74 crore in Mar 2026, reflecting a decrease of 195.98% on a QoQ basis.
- The earnings per share (EPS) of SYSCHEM (INDIA) LTD. stood at ₹0.12 during Jun 2026.
